Tel.: +49 6221 868023
Fax: +49 6221 8680255
info@loxo.de

Aprotinin concentrated solution (for pharmaceutical manufacturing)

For pharmaceutical manufacturing

Description:
Aprotinin is a polyvalent reversible inhibitor of serine proteinases. Aprotinin is a polypeptide of 58 amino acids. Its active center is formed by 4 lysine groups, the tertiary structure shows a pear­shaped unit which fits exactly into the binding site of serine proteinases.

Therapeutic Application:
In a finished dosage form, Aprotinin is used to reduce perioperative blood loss and transfusion requirements in patients at high risk of major blood loss during and following cardiopulmonary bypass (CPB) in the course of coronary artery bypass graft surgery. The effects of aprotinin use in CPB involves a reduction in inflammatory response, through its inhibition of multiple mediators (e.g., kallikrein, plasmin), which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.

MW: 6512

Ki constants:
The following table shows the inhibition of serine proteases:
Enzyme Ki [M]
Trypsin, bovine 6.0·10-14
Trypsinogen, bovine 1.8·10-6
Chymotrypsin, bovine 9.0·10-9
Plasmin, human 2.3·10-10
Kallikrein, pancreatic porcine    1.0·10-9
Kallikrein, urinary porcine 1.7·10-9
Kallikrein, urinary human 0.9·10-10
Kallikrein, plasma porcine 3.0·10-8
Elastase, leukocytes human 3.5·10-6
Urokinase, single chain 27.0·10-6
Urokinase, two chain 25.0·10-6

Activity: Aprotinin solution (~200’000 KIU/ ml)

Storage:
May be used by the expiry date given on the label when stored unopened, protected from moisture, in the dark, 2 -8°C. Avoid contamination of the product by microorganisms. Shipment of product does not require cooling during the time of transportation.

Category: Research use only

Type: Protein

Product Availability: Germany, Israel and Egypt

Manufacturer: DSM Nutritional Products Ltd. Branch Pentapharm, Switzerland

For more information please click .pdf icon below.


Aprotinin concentrated solution

ca.200'000 KIU/ml (for pharmaceutical manufacturing)
Article no.: 807370

Unit: 50 ml

Code: 073-70

Manufacturer: Pentapharm AG

References:

  1. Lemmer JH Jr, Standford W, Bonney SL, et al.
    Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter randomized, double blind, placebo-controlled study.
    J Thorac Cardiovasc Surg. 1994; 107:543-553
  2. Sedrakyan A, Treasure T, Elefteriades JA.
    Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systemic review and meta-analysis of randomized clinical trials.
    J Thorac Cardiovasc Surg. 2004; 128: 442-448.

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzerklärung X